BridgeMD
Human papillomavirus vaccine effectiveness study among men who have sex with men
EU CTIS ID: 2022-502224-49-00
What this study is testing
To assess the direct effectiveness of vaccination with the bivalent HPV vaccine (Cervarix ®) against anal HPV-16/18 infections among men who have sex with men (MSM) aged 19-26 years who visit the Sexual Health Clinic (SHC) of Amsterdam.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- (Group 1, recruited at baseline) Being male and reporting sex with other men in preceding 6 months
- (Group 2, recruited month 24) Being male and reporting sex with other men in the preceding 6 months
- (Group 2, recruited month 24) Age 21-28 years
- (Group 2, recruited month 24) Attending the Sexual Health Clinic in Amsterdam
- (Group 2, recruited month 24) Accepting hypothetically prophylactic HPV vaccination
- (Group 2, recruited month 24) Providing informed consent
You likely can't join if
- (Group 1 & 2) Having been vaccinated with one or more doses of any of the HPV vaccines
- (Group 1 & 2) Not able to read/understand Dutch or English
- (Group 1 & 2) Previous enrolment in the study
- (Group 1 & 2) History of anal cancer or anal intraepithelial neoplasia (AIN)
- (Group 1 & 2) Unlikely to adhere to the study protocol
- (Group 1 & 2) Allergy to one or more components of the vaccine
See the full eligibility criteria
- (Group 1, recruited at baseline) Being male and reporting sex with other men in preceding 6 months
- (Group 2, recruited month 24) Being male and reporting sex with other men in the preceding 6 months
- (Group 2, recruited month 24) Age 21-28 years
- (Group 2, recruited month 24) Attending the Sexual Health Clinic in Amsterdam
- (Group 2, recruited month 24) Accepting hypothetically prophylactic HPV vaccination
- (Group 2, recruited month 24) Providing informed consent
- (Group 1, recruited at baseline) Age 19-26 years
- (Group 1, recruited at baseline) Attending the SHC in Amsterdam
- (Group 1, recruited at baseline) Accepting prophylactic HPV vaccination
- (Group 1, recruited at baseline) Planning to stay in or around Amsterdam over the next two years
- (Group 1, recruited at baseline) Willing and able to return for 1 subsequent visit for vaccination
- (Group 1, recruited at baseline) Willing and able to complete an online questionnaire at month 15
- (Group 1, recruited at baseline) Willing and able to return for a month 24 final study visit
- (Group 1, recruited at baseline) Providing informed consent
- (Group 1 & 2) Having been vaccinated with one or more doses of any of the HPV vaccines
- (Group 1 & 2) Not able to read/understand Dutch or English
- (Group 1 & 2) Previous enrolment in the study
- (Group 1 & 2) History of anal cancer or anal intraepithelial neoplasia (AIN)
- (Group 1 & 2) Unlikely to adhere to the study protocol
- (Group 1 & 2) Allergy to one or more components of the vaccine
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.